Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : COVAC-2
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Vaccine Formulation Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
VIDO’s COVID-19 Vaccine Receives Health Canada Clinical Trial Approval
Details : The authorization from Health Canada enables the Canadian Center for Vaccinology (CCfV) in Halifax to begin recruiting volunteers for the first Phase 1 clinical trial of COVAC-2 vaccine.
Brand Name : COVAC-2
Molecule Type : Vaccine
Upfront Cash : Not Applicable
December 22, 2020
Lead Product(s) : COVAC-2
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Vaccine Formulation Institute
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Dalton Pharma Services
Deal Size : Undisclosed
Deal Type : Partnership
Dalton, VIDO-InterVac Partner to Develop COVID-19 Vax
Details : Under this Partnership, Dalton will be responsible for the formulation and fill/finish of VIDO-InterVac’s COVID-19 vaccine to be used in early Phase clinical trials from Dalton`s cGMP biopharmaceutical facility in Toronto, Canada.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Dalton Pharma Services
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Plant based vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : ZYUS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
Details : ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
May 07, 2020
Lead Product(s) : Plant based vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : ZYUS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?